RecruitingPHASE1, PHASE2NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeiGene
- Principal Investigator
- Study DirectorBeiGene
- Intervention
- BGB-16673(drug)
- Enrollment
- 146 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (29)
- The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
- Anhui Provincial Hospital, Hefei, Anhui, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Beijing Chao Yang Hospital,Capital Medical University, Beijing, Beijing Municipality, China
- Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
- Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong, China
- The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
- Nanyang Central Hospital, Nanyang, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Xiangyang Central Hospital, Xiangyang, Hubei, China
- The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05294731 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn